CD Antigen Cancer Therapy Market to Witness High Growth (2024-2031) | Key Drivers, Segments, and Trends

CD Antigen Cancer Therapy Market Size, Share, Industry, Forecast and Outlook (2024-2031)

<h2>Global CD Antigen Cancer Therapy Market&nbsp;Size, Share &amp; Trends Analysis Report By Product Type, By Type, By Therapy Type, By End-user, By Region, And Segment Forecasts, 2024 &ndash; 2031</h2>

<h3>Market Overview</h3>

<blockquote>
Global CD Antigen Cancer Therapy Market reached US$ YY&nbsp;million in 2023 and is expected to reach US$ YY&nbsp;million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031
</blockquote>

CD markers, or CD antigens, are molecules found on cell surfaces that differentiate cell types. They detect abnormal growth of cells called neoplasm, which can be benign, malignant, or precancerous. CD markers are crucial in cancer diagnosis and can help identify successful treatment types and measure treatment effectiveness by monitoring changes in relevant CD markers.&nbsp;

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Size Available for Years
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2022-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Estimation Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2024-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Revenue Units
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Product Type, Type, Therapy Type, End User
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For more details on this report &ndash; <a href="https://www.datamintelligence.com/download-sample/cd-antigen-cancer-therapy-market" target="_blank">Request for Sample</a>

<h3>&nbsp;</h3>

<h3>Market Dynamics: Drivers &amp; Restraints</h3>

Rise in shift towards personalized medicine

The CD Antigen Cancer Therapy market is experiencing a significant shift towards personalized medicine, with healthcare professionals choosing the most appropriate treatment based on a patient&#39;s unique biological characteristics. This approach, such as CAR-T cell therapy, directly targets the molecular characteristics of the cancer, maximizing therapy success while minimizing side effects.&nbsp;

The market is also expanding by exploring novel CD antigens beyond CD19 and CD20, allowing researchers to design therapies for tumors that may not respond adequately to CDI 9-targeted treatments. Advancements in gene editing technologies like CRISPR are also facilitating next-generation CAR-T therapies, allowing for precise adjustments to immune cells&#39; genetic makeup, boosting CAR-T cell performance and endurance. These developments open the door to next-generation CAR-T therapies that improve potency, safety, and longevity, advancing our quest for more efficient cancer treatments.

Complications associated with drugs&nbsp;

CD Antigens drugs in cancer therapy have side effects like weakness, burning eyes, slow heart rate, chest pain, wheezing, dry cough, shortness of breath, high blood sugar, ketoacidosis, low blood cell counts, liver problems, and stomach problems. Short-acting and long-acting versions have been found to be dangerous, limiting market growth.

<h3>Segment Analysis</h3>

The global CD antigen cancer therapy market is segmented based on product type, type, therapy, end-user and region.

The monoclonal antibodies from the product type segment accounted for approximately 62.3% of the CD antigen cancer therapy&nbsp; market share

The monoclonal antibodies from the product type segment accounted for approximately 42.3%. Monoclonal antibodies segment is expecte to have highest market share due to their high specificity to cancer cells and ability to bind to surface proteins, are poised to gain a significant market share in the CD Antigen Cancer Therapy market due to their potential in cancer treatment.

The robust investments by global pharmaceutical entities in the research and development of cancer biologics, particularly monoclonal antibodies, reflect their efficacy and low toxicity profile compared to conventional chemotherapy. Approval procedures for new cancer monoclonal antibodies contribute to the market&#39;s expansion. For instance, the conditional approval of trastuzumab deruxtecan in the European Union for HER2-positive breast cancer treatment in January 2023 exemplifies regulatory responsiveness to innovative therapies.

<h3>Geographical Analysis</h3>

North America is estimated to hold about 42.4% of the total market share throughout the forecast period 

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like robust healthcare infrastructure, coupled with high adoption rates of advanced medical technologies, and substantial investments in cancer, R&amp;D and the adoption of cancer therapy and the significant burden of cancer cases, particularly in the United States and Canada.&nbsp;

For instance, data released by the Canadian Cancer Society in November 2023 revealed that approximately 239, 100 individuals in Canada were diagnosed with cancer in 2023 alone. Also, it is projected that an estimated 2 out of 5 Canadians will develop cancer at some point during their lifetime. This high prevalence highlights the urgent need for efficient remedy processes to the lead in tackling the problems caused by cancer.&nbsp;

<h3>Covid 19 Impact Analysis</h3>

The COVID-19 pandemic has significantly impacted the CD antigen cancer therapy market in various ways. The pandemic led to disruptions in clinical trials, with many studies being delayed or temporarily halted due to lockdowns and reallocation of healthcare resources to manage COVID-19 cases. This affected the development timelines for new therapies targeting CD antigens. Additionally, supply chain interruptions hindered the production and distribution of essential research materials and therapeutic products.&nbsp;

<h3>Market Segmentation</h3>

By Product Type

<ul>
	<li>Monoclonal Antibodies</li>
	<li>Antibody-drug conjugates</li>
	<li>CAR-T Cell Therapies</li>
	<li>Тrі-Funсtіоnаl аnd Ві-Ѕресіfіс Т-Сеll Еngаgеr Аntіbоdіеѕ</li>
	<li>Others</li>
</ul>

By Type

<ul>
	<li>CD19</li>
	<li>CD20</li>
	<li>CD22</li>
	<li>CD30</li>
	<li>Others</li>
</ul>

By Therapy Type

<ul>
	<li>Targeted Therapy</li>
	<li>Immunotherapy</li>
	<li>Combination Therapy</li>
	<li>Monotherapy</li>
	<li>Others</li>
</ul>

By End-User

<ul>
	<li>Hospitals</li>
	<li>Cancer research centers</li>
	<li>Clinics</li>
	<li>Others&nbsp;</li>
</ul>

By Region

<ul>
	<li>North America
	<ul>
		<li>U.S.</li>
		<li>Canada</li>
		<li>Mexico</li>
	</ul>
	</li>
	<li>Europe
	<ul>
		<li>Germany</li>
		<li>UK</li>
		<li>France</li>
		<li>Italy</li>
		<li>Spain</li>
		<li>Rest of Europe</li>
	</ul>
	</li>
	<li>South America
	<ul>
		<li>Brazil</li>
		<li>Argentina</li>
		<li>Rest of South America</li>
	</ul>
	</li>
	<li>Asia-Pacific
	<ul>
		<li>China</li>
		<li>India</li>
		<li>Japan</li>
		<li>South Korea</li>
		<li>Rest of Asia-Pacific</li>
	</ul>
	</li>
	<li>Middle East and Africa</li>
</ul>

<h3>Competitive Landscape</h3>

The major global players in the market include Seattle Genetics Inc, АrуоGеn Віорhаrmа, Віосаd, Віоgеn Іdес, Сеlltrіоn, Gеnеntесh, Gеnmаb, Merck, Sandoz, Eli Lilly the Company among others.

<h3>Key Developments</h3>

<ul>
	<li>In April 2023, The USFDA approved Genentech, a Roche Group company, for use of Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) as a cancer therapy medication. The medication is used to treat adult patients with diffuse large B-cell lymphoma (DLBCL) who have not had prior treatment.</li>
	<li>In April 2023, Omisirge (omidubicel-onlv), an allogeneic cell treatment developed by Gamida Cell Ltd, was approved by the USFDA for use in treating hematologic malignancies in adults and children patients aged 12 years and above.</li>
</ul>

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global CD antigen cancer therapy market segmentation based on product type, type, therapy type, end user and region as well as understand key commercial assets and players.</li>
	<li>identify commercial opportunities by analyzing trends and co-development.&nbsp;</li>
	<li>excel data sheet with numerous data points of the CD antigen cancer therapy market level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as excel consisting of key products of all the major players.</li>
</ul>

The global CD antigen cancer therapy market report would provide approximately 64 tables, 61 figures and 186 pages.

<h3>Target Audience 2024</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Product Type</li>
		<li>Snippet by Type</li>
		<li>Snippet by Therapy Type</li>
		<li>Snippet by End User</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Rise in shift towards personalized medicine</li>
				<li>Rise of advancements in treatment options</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Complications associated with drugs&nbsp;</li>
				<li>XX</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Patent Analysis</li>
		<li>PESTLE Analysis</li>
		<li>SWOT Analysis</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Product Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Attractiveness Index, By Product Type</li>
		</ol>
		</li>
		<li>Monoclonal Antibodies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Antibody-drug conjugates</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">CAR-T Cell Therapies</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Тrі-Funсtіоnаl аnd Ві-Ѕресіfіс Т-Сеll Еngаgеr Аntіbоdіеѕ</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Others</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type</li>
		</ol>
		</li>
		<li>CD19*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">CD20</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">CD22</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">CD30</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Others</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Therapy Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Attractiveness Index, By Therapy Type</li>
		</ol>
		</li>
		<li>Targeted Therapy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Immunotherapy</li>
		<li>Combination Therapy</li>
		<li>Monotherapy</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End User</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Attractiveness Index, By End User</li>
		</ol>
		</li>
		<li>Hospitals*
		<ol>
			<li>Introduction
			<ol>
				<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Cancer research centers</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Clinics</h3>
		</li>
		<li>
		<h3 style="color:#1f3863; font-style:normal">Others</h3>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>South Korea</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Seattle Genetics Inc*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>АrуоGеn Віорhаrmа</li>
		<li>Віосаd</li>
		<li>Віоgеn Іdес</li>
		<li>Сеlltrіоn</li>
		<li>Gеnеntесh</li>
		<li>Gеnmаb</li>
		<li>Merck</li>
		<li>Sandoz</li>
		<li>Eli Lilly the Company&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global CD Antigen Cancer Therapy Market Value, By Product Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 2 Global CD Antigen Cancer Therapy Market Value, By Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 3 Global CD Antigen Cancer Therapy Market Value, By Therapy Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 4 Global CD Antigen Cancer Therapy Market Value, By End-User, 2023, 2027 &amp; 2031 (US$ Million)

Table 5 Global CD Antigen Cancer Therapy Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 6 Global CD Antigen Cancer Therapy Market Value, By Product Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 7 Global CD Antigen Cancer Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 8 Global CD Antigen Cancer Therapy Market Value, By Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 9 Global CD Antigen Cancer Therapy Market Value, By Type, 2022-2031 (US$ Million)

Table 10 Global CD Antigen Cancer Therapy Market Value, By Therapy Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 11 Global CD Antigen Cancer Therapy Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 12 Global CD Antigen Cancer Therapy Market Value, By End-User, 2023, 2027 &amp; 2031 (US$ Million)

Table 13 Global CD Antigen Cancer Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 14 Global CD Antigen Cancer Therapy Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 15 Global CD Antigen Cancer Therapy Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America CD Antigen Cancer Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 17 North America CD Antigen Cancer Therapy Market Value, By Type, 2022-2031 (US$ Million)

Table 18 North America CD Antigen Cancer Therapy Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 19 North America CD Antigen Cancer Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 North America CD Antigen Cancer Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Asia-Pacific CD Antigen Cancer Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 22 Asia-Pacific CD Antigen Cancer Therapy Market Value, By Type, 2022-2031 (US$ Million)

Table 23 Asia-Pacific CD Antigen Cancer Therapy Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 24 Asia-Pacific CD Antigen Cancer Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 25 Asia-Pacific CD Antigen Cancer Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe CD Antigen Cancer Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 27 Europe CD Antigen Cancer Therapy Market Value, By Type, 2022-2031 (US$ Million)

Table 28 Europe CD Antigen Cancer Therapy Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 29 Europe CD Antigen Cancer Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 30 Europe CD Antigen Cancer Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 31 South America CD Antigen Cancer Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 32 South America CD Antigen Cancer Therapy Market Value, By Type, 2022-2031 (US$ Million)

Table 33 South America CD Antigen Cancer Therapy Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 34 South America CD Antigen Cancer Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 35 South America CD Antigen Cancer Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East and Africa CD Antigen Cancer Therapy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 37 Middle East and Africa CD Antigen Cancer Therapy Market Value, By Type, 2022-2031 (US$ Million)

Table 38 Middle East and Africa CD Antigen Cancer Therapy Market Value, By Therapy Type, 2022-2031 (US$ Million)

Table 39 Middle East and Africa CD Antigen Cancer Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 40 Middle East and Africa CD Antigen Cancer Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 41 Seattle Genetics Inc: Overview

Table 42 Seattle Genetics Inc: Product Portfolio

Table 43 Seattle Genetics Inc: Key Developments

Table 44 АrуоGеn Віорhаrmа: Overview

Table 45 АrуоGеn Віорhаrmа: Product Portfolio

Table 46 АrуоGеn Віорhаrmа: Key Developments

Table 47 Віосаd: Overview

Table 48 Віосаd: Product Portfolio

Table 49 Віосаd: Key Developments

Table 50 Віоgеn Іdес: Overview

Table 51 Віоgеn Іdес: Product Portfolio

Table 52 Віоgеn Іdес: Key Developments

Table 53 Сеlltrіоn: Overview

Table 54 Сеlltrіоn: Product Portfolio

Table 55 Сеlltrіоn: Key Developments

Table 56 Gеnеntесh: Overview

Table 57 Gеnеntесh: Product Portfolio

Table 58 Gеnеntесh: Key Developments

Table 59 Gеnmаb: Overview

Table 60 Gеnmаb: Product Portfolio

Table 61 Gеnmаb: Key Developments

Table 62 Merck : Overview

Table 63 Merck : Product Portfolio

Table 64 Merck : Key Developments

Table 65 Sandoz: Overview

Table 66 Sandoz: Product Portfolio

Table 67 Sandoz: Key Developments

Table 68 Eli Lilly the Company: Overview

Table 69 Eli Lilly the Company: Product Portfolio

Table 70 Eli Lilly the Company: Key Developments

List of Figures

Figure 1 Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 2 Global CD Antigen Cancer Therapy Market Share, By Product Type, 2023 &amp; 2031 (%)

Figure 3 Global CD Antigen Cancer Therapy Market Share, By Type, 2023 &amp; 2031 (%)

Figure 4 Global CD Antigen Cancer Therapy Market Share, By Therapy Type, 2023 &amp; 2031 (%)

Figure 5 Global CD Antigen Cancer Therapy Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 6 Global CD Antigen Cancer Therapy Market Share, By Region, 2023 &amp; 2031 (%)

Figure 7 Global CD Antigen Cancer Therapy Market Y-o-Y Growth, By Product Type, 2023-2031 (%)

Figure 8 Monoclonal Antibodies CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 9 Antibody-drug conjugates CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 10 CAR-T Cell Therapies CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 11 Тrі-Funсtіоnаl аnd Ві-Ѕресіfіс Т-Сеll Еngаgеr Аntіbоdіеѕ CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 12 Others CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 13 Global CD Antigen Cancer Therapy Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 14 CD19 Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 15 CD20 Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 16 CD22 Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 17 CD30 Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 18 Others Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 19 Global CD Antigen Cancer Therapy Market Y-o-Y Growth, By Therapy Type, 2023-2031 (%)

Figure 20 Targeted Therapy Therapy Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 21 Immunotherapy Therapy Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 22 Combination Therapy Therapy Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 23 Monotherapy Therapy Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 24 Others Therapy Type in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 25 Global CD Antigen Cancer Therapy Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 26 Hospitals End-User in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 27 Cancer research centers End-User in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 28 Clinics End-User in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 29 Others End-User in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 30 C5 End-User in Global CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 31 Global CD Antigen Cancer Therapy Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 32 North America CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 33 North America CD Antigen Cancer Therapy Market Share, By Product Type, 2023 &amp; 2031 (%)

Figure 34 North America CD Antigen Cancer Therapy Market Share, By Type, 2023 &amp; 2031 (%)

Figure 35 North America CD Antigen Cancer Therapy Market Share, By Therapy Type, 2023 &amp; 2031 (%)

Figure 36 North America CD Antigen Cancer Therapy Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 37 North America CD Antigen Cancer Therapy Market Share, By Country, 2023 &amp; 2031 (%)

Figure 38 Asia-Pacific CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 39 Asia-Pacific CD Antigen Cancer Therapy Market Share, By Product Type, 2023 &amp; 2031 (%)

Figure 40 Asia-Pacific CD Antigen Cancer Therapy Market Share, By Type, 2023 &amp; 2031 (%)

Figure 41 Asia-Pacific CD Antigen Cancer Therapy Market Share, By Therapy Type, 2023 &amp; 2031 (%)

Figure 42 Asia-Pacific CD Antigen Cancer Therapy Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 43 Asia-Pacific CD Antigen Cancer Therapy Market Share, By Country, 2023 &amp; 2031 (%)

Figure 44 Europe CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 45 Europe CD Antigen Cancer Therapy Market Share, By Product Type, 2023 &amp; 2031 (%)

Figure 46 Europe CD Antigen Cancer Therapy Market Share, By Type, 2023 &amp; 2031 (%)

Figure 47 Europe CD Antigen Cancer Therapy Market Share, By Therapy Type, 2023 &amp; 2031 (%)

Figure 48 Europe CD Antigen Cancer Therapy Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 49 Europe CD Antigen Cancer Therapy Market Share, By Country, 2023 &amp; 2031 (%)

Figure 50 South America CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 51 South America CD Antigen Cancer Therapy Market Share, By Product Type, 2023 &amp; 2031 (%)

Figure 52 South America CD Antigen Cancer Therapy Market Share, By Type, 2023 &amp; 2031 (%)

Figure 53 South America CD Antigen Cancer Therapy Market Share, By Therapy Type, 2023 &amp; 2031 (%)

Figure 54 South America CD Antigen Cancer Therapy Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 55 South America CD Antigen Cancer Therapy Market Share, By Country, 2023 &amp; 2031 (%)

Figure 56 Middle East and Africa CD Antigen Cancer Therapy Market Value, 2022-2031 (US$ Million)

Figure 57 Middle East and Africa CD Antigen Cancer Therapy Market Share, By Product Type, 2023 &amp; 2031 (%)

Figure 58 Middle East and Africa CD Antigen Cancer Therapy Market Share, By Type, 2023 &amp; 2031 (%)

Figure 59 Middle East and Africa CD Antigen Cancer Therapy Market Share, By Therapy Type, 2023 &amp; 2031 (%)

Figure 60 Middle East and Africa CD Antigen Cancer Therapy Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 61 Seattle Genetics Inc: Financials

Figure 62 АrуоGеn Віорhаrmа: Financials

Figure 63 Віосаd: Financials

Figure 64 Віоgеn Іdес: Financials

Figure 65 Сеlltrіоn: Financials

Figure 66 Gеnеntесh: Financials

Figure 67 Gеnmаb: Financials

Figure 68 Merck : Financials

Figure 69 Sandoz: Financials

Figure 70 Eli Lilly the Company: Financials

CD Antigen Cancer Therapy Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Glioblastoma Multiforme Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 June 04

Starting from

Hodgkin’s Lymphoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 October 15

Starting from

Bone Cancer Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 September 12

Starting from

Thymus Cancer Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 November 12

Starting from

Oncology Therapy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 May 21

Starting from

Cancer Vaccines Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 03

Starting from